Skip to main content
SpringerLink
Log in

Maternal Serum Aneuploidy Screen and Adverse Pregnancy Outcomes

  • Original Article
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

Abstract

Objective

To find out whether maternal serum screening for fetal chromosomal aneuploidy predicts adverse pregnancy outcomes.

Methods

A two-year retrospective case–control study was conducted at a tertiary hospital. Pregnant women with a high-risk serum screen but with chromosomally normal fetuses (n = 189) were compared to those with low-risk screen (controls, n = 157) for adverse pregnancy outcomes.

Results

Women with high-risk double marker or combined screen were found to have higher prevalence of LBW [OR 2.56; 95 % CI (1.01–6.53), p < 0.05] and PT [OR 2.93; 95 % CI (1.11–7.65), p < 0.05], while women with high-risk triple screen had higher prevalence of PIH [OR 3.72; 95 % CI (1.23–11.18); p < 0.05], Oligo [OR 4.50; 95 % CI (1.30–15.64); p < 0.05], delivery by C-section [OR 2.51; 95 % CI (1.41–4.47); p < 0.005] as compared to low-risk women. PAPP-A was found to be a significant predictor of birth weight (R 2 = 12.2 %, β ± SE = 0.224 ± 0.069; p < 0.005) and gestational age (R 2 = 4.9 %, β ± SE = 0.613 ± 0.296; p < 0.05). Beta hCG in first and hCG in second trimester predicted oligohydramnios (R 2 = 9.2 %, β ± SE = −0.077 ± 0.025; p < 0.005). The areas under the ROC curves of PAPP-A for LBW and PT were 0.70(p < 0.01) and 0.684 (p < 0.05), respectively.

Conclusion

A “high-risk” maternal serum screen with abnormal PAPP-A and/or beta hCG/HCG is associated with adverse pregnancy outcomes and may help identifying women requiring additional fetal surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cole LA. Biological functions of hCG and hCG related molecules. Reprod Biol Endocrinol. 2010;8:102.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Morris RK, Cnossen JS, Langejans M, et al. Serum screening with Down’s syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2008;8:33.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dane B, Dane C, Batmaz G, et al. First trimester maternal serum pregnancy-associated plasma protein-A is a predictive factor for early preterm delivery in normotensive pregnancies. Gynecol Endocrinol. 2013;29(6):592–5.

    Article  CAS  PubMed  Google Scholar 

  4. Spencer K, Cowans NJ, Avgidou KA, et al. First trimester biochemical markers of aneuploidy and the prediction of small for gestational age fetuses. Ultrasound Obstet Gynecol. 2008;31:15–9.

    Article  CAS  PubMed  Google Scholar 

  5. Canini S, Prefumo F, Pastorino D, et al. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertil Steril. 2008;89(1):174–8.

    Article  CAS  PubMed  Google Scholar 

  6. Patil M, Panchanadikar TM, Wagh G. Variation of papp-a level in the first trimester of pregnancy and its clinical outcome. J Obstet Gynaecol India. 2014;64(2):116–9.

    Article  PubMed  Google Scholar 

  7. Hsieh TT, Hung TH, Hsu JJ, et al. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population. Obstet Gynecol. 1997;89(6):937–40.

    Article  CAS  PubMed  Google Scholar 

  8. Duric K, Skrablin S, Lesin J, et al. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol. 2003;110(1):12–5.

    Article  CAS  PubMed  Google Scholar 

  9. Sritippayawan S, Vachirasrisoontra C. Adverse pregnancy outcomes after a false-positive second trimester serum screen for Down syndrome in Thai pregnant women. J Med Assoc Thai. 2005;88(4):449–54.

    PubMed  Google Scholar 

  10. Morssink LP, Kornman LH, Hallahan TW, et al. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn. 1998;18(2):147–52.

    Article  CAS  PubMed  Google Scholar 

  11. Schnettler WT, Hacker MR, Barber RE, et al. Management of abnormal serum markers in the absence of aneuploidy and neural tube defects. J Matern Fetal Neonatal Med. 2012;25(10):1895–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918–49.

    Article  PubMed  Google Scholar 

  13. D’Antonio F, Rijo C, Thilaganathan B, et al. Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications. Prenat Diagn. 2013;33(9):839–47.

    Article  PubMed  Google Scholar 

  14. Tape TG. Interpreting diagnostic tests. http://gim.unmc.edu/dxtests/Default.htm (2014). Accessed 22 Dec 2014.

  15. Ardawi MS, Nasrat HA, Rouzi AA, et al. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10–13(+6) weeks in relation to co-variables in pregnant Saudi women. Prenat Diagn. 2007;27(4):303–11.

    Article  PubMed  Google Scholar 

  16. Wright D, Abele H, Baker A, et al. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol. 2011;38(3):309–13.

    Article  CAS  PubMed  Google Scholar 

  17. Quattrocchi T, Baviera G, Pochiero T, et al. Maternal serum PAPP-A as an early marker of obstetric complications? Fetal Diagn Ther. 2015;37(1):33–6.

    Article  PubMed  Google Scholar 

  18. Sharp AN, Alfirevic Z. First trimester screening can predict adverse pregnancy outcomes. Prenat Diagn. 2014;34(7):660–7.

    PubMed  Google Scholar 

  19. Halscott TL, Ramsey PS, Reddy UM. First trimester screening cannot predict adverse outcomes yet. Prenat Diagn. 2014;34(7):668–76.

    PubMed  Google Scholar 

  20. Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013;41(5):491–9.

    Article  CAS  PubMed  Google Scholar 

  21. Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomized placebo-controlled PREDO trial and a meta-analysis of randomized trials. Br J Obstet Gynaecol. 2013;120(1):64–74.

    Article  CAS  Google Scholar 

  22. Moore GS, Allshouse AA, Post AL, et al. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU high-risk aspirin study. Tang J Perinatol. 2014;. doi:10.1038/jp.2014.214.

    Google Scholar 

  23. Henderson JT, O’Connor E, Whitlock EP. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia. Ann Intern Med. 2014;161(8):613–4.

    Article  PubMed  Google Scholar 

  24. Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30(1–2):260–79.

    Article  CAS  PubMed  Google Scholar 

  25. Huynh L, Kingdom J, Akhtar S. Low pregnancy-associated plasma protein A level in the first trimester. Can Fam Physician. 2014;60(10):899–903.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by Deenanath Mangeshkar Hospital and Research Center.

Author information

Authors and Affiliations

  1. Department of Genetic Medicine, Deenanath Mangeshkar Hospital and Research Center, Erandawane, Pune, 411004, India

    Koumudi Godbole

  2. Fetal Medicine Unit, Deenanath Mangeshkar Hospital and Research Center, Pune, India

    Aparna Kulkarni

  3. Department of Research, Deenanath Mangeshkar Hospital and Research Center, Pune, India

    Asawari Kanade

  4. Department of Obstetrics and Gynecology, Deenanath Mangeshkar Hospital and Research Center, Pune, India

    Shilpa Kulkarni, Girish Godbole & Anuradha Wakankar

Authors
  1. Koumudi Godbole
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aparna Kulkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asawari Kanade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shilpa Kulkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Girish Godbole
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anuradha Wakankar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koumudi Godbole.

Ethics declarations

Conflicts of interest

None.

Human and Animals Rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

Informed consent waived off for retrospective study.

Additional information

Koumudi Godbole MD, FCCMG, is Consultant Clinical Geneticist in Department of Genetic Medicine, Deenanath Mangeshkar Hospital and Research Center, Pune, India; Aparna Kulkarni MD, MRCOG, M Phil, is Consultant in Fetal Medicine, Deenanath Mangeshkar Hospital and Research Center, Pune, India; Asawari Kanade PhD, is Consultant Statistician in Department of Research, Deenanath Mangeshkar Hospital and Research Center, Pune, India; Shilpa Kulkarni BHMS, is Coordinator in Prenatal Medicine Program, Deenanath Mangeshkar Hospital and Research Center, Pune, India; Girish Godbole MD, is Consultant Obstetrician and Gynecologist in Deenanath Mangeshkar Hospital and Research Center, Pune, India; Anuradha Wakankar MS, MRCOG, is Consultant Obstetrician and Gynecologist in Deenanath Mangeshkar Hospital and Research Center, Pune, India.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Godbole, K., Kulkarni, A., Kanade, A. et al. Maternal Serum Aneuploidy Screen and Adverse Pregnancy Outcomes. J Obstet Gynecol India 66 (Suppl 1), 141–148 (2016). https://doi.org/10.1007/s13224-015-0826-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13224-015-0826-2

Keywords

Search

Navigation